查詢結果分析
相關文獻
- A Phase Ⅱ Study of Irinotecan in Combination with Cisplatin as Second-line Chemotherapy in Patients with Metastatic or Locally Advanced Gastric Cancer
- 胃癌化學治療之進展
- Rarely Reported Liver Toxicity in Patients Who were Hepatitis B Carrier and Underwent Chemoirradiation for Gastric Cancer
- The Role of Extended Lymphadenectomy and Adjuvant Immunochemotherapy for Gastric Cancer
- 胃癌之化學治療
- Recent Advances in Therapy for Gastric Cancer
- Treatment Outcome in Patients with Locally Advanced Gastric Cancer Receiving Adjuvant Chemoradiotherapy
- Treatment of Metastatic or Recurrent Gastric Cancer with Weekly 24-hour Infusion of Cisplatin and High-Dose 5-Fluorouracil/Leucovorin in an Outpatient Setting
- Chemotherapy and Radiotherapy in Gastric Cancer
- 無法手術或轉移性胃癌之治療
頁籤選單縮合
題 名 | A Phase Ⅱ Study of Irinotecan in Combination with Cisplatin as Second-line Chemotherapy in Patients with Metastatic or Locally Advanced Gastric Cancer=合併Irinotecan及Cisplatin用於第二線晚期胃癌病患第二期臨床試驗 |
---|---|
作 者 | 沈雯琪; 楊再勝; 徐鴻智; 陳仁熙; | 書刊名 | 長庚醫誌 |
卷 期 | 34:6 2011.11-12[民100.11-12] |
頁 次 | 頁590-598 |
分類號 | 416.243 |
關鍵詞 | 胃癌; 化學治療; 益立諾; 鉑金; Gastric cancer; Chemotherapy; Irinotecan; Cisplatin; |
語 文 | 英文(English) |
英文摘要 | Background: Gastric cancer remains one of the leading causes of cancer death worldwide. Currently, no standard secondary-line chemotherapy for locally advanced or metastatic gastric cancer is recommended. The aim of this study is to demonstrate and confirm the overall objective response rate to irinotecan plus cisplatin for previously treated patients with metastatic or locally advanced gastric cancer in Taiwan. Methods: Patients in this study had been diagnosed with gastric adenocarcinoma with evidence of advanced disease and had failure of first line chemotherapy or documented disease progression while receiving adjuvant chemotherapy. Patients had good Eastern Cooperative Oncology Group performance status and adequate hematologic, renal and liver function. Patients received irinotecan 60 mg/m2 followed by cisplatin 30 mg/m2 on days 1 and 8, every 3 weeks. Treatment was administered until disease progression, intolerable toxicity or consent withdrawal. Evaluation was conducted every two cycles using the Response Evaluation Criteria in Solid Tumors. The toxicity was recorded by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0, year 2003. Results: From January 2007 to December 2008, 24 patients were enrolled. Their median age was 54 years (range 30 to 77 years). Fifteen patients (63%) were men. Five patients (21%) achieved partial response, while ten patients (42%) remained stable. The median progression-free survival was 109 days and median overall survival was 222 days. The major grade 3/4 toxicities were neutropenia (20.9%) and diarrhea (8.3%). Conclusions: Second-line chemotherapy with irinotecan and cisplatin for advanced gastric cancer is effective and has acceptable toxicity. |
本系統中英文摘要資訊取自各篇刊載內容。